Notably, edaravone, a free radical scavenger drug currently in clinical trials for various neurological disorders, has been shown to be neuroprotective by enhancing expression of BDNF, Bcl-2 and suppressing caspase-3 activity [73]. Here, BCL2 is linked to nervous system disorder.